Skip to main content

Table 4 The completion rate by primary disease and surgical procedure

From: A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)

 

Primary disease

Total

Extrahepatic

Intrahepatic

Gallbladder

Ampulla of Vater

(a) Full analysis set (n = 46)

 Pancreatoduodenectomy

6 /15 (40.0%)

–

1/1 (100%)

5/9 (55.6%)

12/25 (48.0%)

 Hepatectomy without bile duct resection

–

4/6 (66.7%)

–

–

4/6 (66.7%)

 Hepatectomy with bile duct resection

2/4 (50.0%)

1/2 (50.0%)

–

–

3/6 (50.0%)

 Extended cholecystectomy

–

–

6/9 (66.7%)

–

6/9 (66.7%)

 Total

8/19 (42.1%)

5/8 (62.5%)

7/10 (70.0%)

5/9 (55.6%)

25/46 (54.3%)

(b) Cases excluding recurrent cases (n = 40)

 Pancreatoduodenectomy

6/13 (46.2%)

–

1/1 (100%)

5/6 (83.3%)

12/20 (60.0%)

 Hepatectomy without bile duct resection

–

4/6 (66.7%)

 

–

4/6 (66.7%)

 Hepatectomy with bile duct resection

2/4 (50.0%)

1/1 (100%)

–

–

3/5 (60.0%)

 Extended cholecystectomy

–

–

6/9 (66.7%)

–

6/9 (66.7%)

 Total

8/17 (47.1%)

5/7 (71.4%)

7/10 (70.0%)

5/6 (83.3%)

25/40 (62.5%)